Skip to main content

Advertisement

SpringerLink
Log in

Antipsychotics Induced Movement and Sleep Disorder on Patients with Schizophrenia Attending Follow-Up Service

  • Original Article
  • Published:
Sleep and Vigilance Aims and scope Submit manuscript

Abstract

Background

Antipsychotics medication has unwanted effects which occurred during the initiation and withdrawal of neuroleptics. It results in poor adherence, stigma, and difficulties in performing day-to-day activities. Early identifying and managing side effects is very vital for the better management of psychiatric patient.

Methods

This study was a hospital-based cross-sectional study design conducted using a systematic random sampling from 12 March to 12 April 2019 St. Amanuel Mental Specialized Hospital. The Diagnostic and Statistical Manual of Mental Disorders Four (DSM-IV) diagnostic criteria were used to assess the neuroleptic-induced movement disorder. Multiple logistic regression model was used to identify factors associated with the outcome variable at 95% CI (p < 0.05).

Result

This study included 417 respondents. The magnitude of neuroleptic-induced movement disorder was 48.5%. Haloperidol (AOR = 3.37, 2.34–4.12), Modecate (AOR = 1.78,1.10–3.12), khat use (AOR = 2.55, 2.12–3.90), tobacco use (AOR = 3.21, 2.11–5.32), duration of treatment less than 5 years (AOR = 2.33, 2.12–3.02), Haloperidol > 10 mg (AOR = 3.73, 3.44–4.74), Modicate (AOR = 3.23, 2.78–3.99), Risperidone > 4 mg (AOR = 2.10, 1.83–3.56), family history side effect (1.68, 95% CI, 1.22–2.43), and poor social support (AOR = 2.66, 2.55–3.21) were significantly associated with the outcome variable at 95% CI, p < 0.05.

Conclusion

Out of all, half of them were having neuroleptic-induced movement disorder. Periodic and close monitoring is essential to identify and intrude drug-induced movement disorders early as soon as possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Availability of Data

The data sets used in this study were available from the corresponding author on reasonable request.

Abbreviations

NIMD:

Neuroleptic-induced movement disorder

CI:

Confidence interval

COR:

Crude odd ratio

AOR:

Adjusted odds ratio

IM:

Intramuscular

SPSS:

Statistical package for social sciences

DSM-V:

Diagnostic and statistical manual

OSS:

Oslo social support

References

  1. Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand. 1996;94:118–24.

    Article  CAS  Google Scholar 

  2. Miller CH. Fleishhacker, managing antipsychotic-induced acute and chronic akathisia. Drug Safeguard. 2000;22(3):73–81.

    Article  CAS  Google Scholar 

  3. Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J. 2009;85:322–6.

    Article  CAS  Google Scholar 

  4. Ertugrul A. Demir B (2005) Clozapine-induced tardive dyskinesia: a case report. Prog Neuro Psychochem Biol Psychiatry. 2005;29(3):633–5.

    Google Scholar 

  5. Kirgaval RS. Prevalence of extrapyramidal side effects in patients on antipsychotics drugs at a tertiary care centre. J Psychiatry. 2017;20:419. https://doi.org/10.4172/2378-5756.1000419.

    Article  Google Scholar 

  6. Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry. 1998;59(3):21–5.

    PubMed  Google Scholar 

  7. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63(4):1121–8.

    Article  Google Scholar 

  8. Divac N. Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Central. 2014;65(5):63–70.

    Google Scholar 

  9. Casey DE. Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr. 2006;11(7):25–31.

    Article  Google Scholar 

  10. Llorca P. Tardive dyskinesia’s and antipsychotics: a review. Eur Psychiatry. 2002;17(3):129–38.

    Article  Google Scholar 

  11. Hennessy G, O’Brien CP. Treatment of patients with substance use disorders. Am J Psychiatry. 2006;163(10):5–82.

    PubMed  Google Scholar 

  12. Xiang YT. Sex differences in use of psychotropic drugs and drug-induced side effects in schizophrenia patients. Austin J Psychiatry. 2011;45:193–8.

    Article  Google Scholar 

  13. Zhornitsky S. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in non-abusing patients with schizophrenia. Mov Disord. 2010;25:2188–94.

    Article  Google Scholar 

  14. Rosenheck R. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br J Psychiatry. 2007;19(3):238–45.

    Article  Google Scholar 

  15. Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J. 2009;85(2):322–6.

    Article  CAS  Google Scholar 

  16. Milana P. Extrapyramidal syndromes caused by antipsychotics. J Med Preg. 2012;65(11):521–6.

    Google Scholar 

  17. Taye H. Antipsychotic medication induced movement disorders: the case of Amanuel specialized mental hospital, Addis Ababa, Ethiopia. Am J Psychiatry Neurosci. 2014;2(5):76–82.

    Article  Google Scholar 

  18. Van Putten T. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry. 1984;41(6):1036–9.

    Article  Google Scholar 

  19. Marek K. The treatment of neuroleptic-induced extrapyramidal symptoms. J Psychiatry. 2016;13(1):47–50.

    Google Scholar 

  20. Nevena D. Second-generation antipsychotics and extrapyramidal adverse effects. Hinadwi J Central Nerv Syst. 2014;5(2):23–7.

    Google Scholar 

  21. Barzilai N. The critical role of metabolic pathways in aging. Diabetes. 2012;61:1315–22.

    Article  CAS  Google Scholar 

  22. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:14.

    Google Scholar 

  23. Darbin O. The aging striatal dopamine function. Parkinsonism Relat Disord. 2012;18:426–32.

    Article  Google Scholar 

  24. Targum SD. Treating psychotic symptoms in elderly patients. Primary care companion. J Clin Psychiatry. 2001;3:156–63.

    Google Scholar 

  25. Zhornitsky S, Stip E, Pampoulova T, et al. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in non-abusing patients with schizophrenia. Mov Disord. 2010;25:2188–94.

    Article  Google Scholar 

  26. Dixon L, Weiden PJ, Haas G, et al. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Comp Psychiatry. 1992;33:121–2.

    Article  CAS  Google Scholar 

  27. Casey E. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol. 1995;10(3):105–14.

    PubMed  Google Scholar 

  28. Lehan AF, Lieberman JA, Dixon JA, et al. Practice guideline for the treatment of schizophrenia. 2nd ed. Washington, DC: American Psychiatric Association; 2004.

    Google Scholar 

  29. Thnvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J. 2009;85(1004):322–6.

    Article  Google Scholar 

  30. Dressler D, Benecke R. Diagnosis and management of acute movement disorders. J Neurology. 2005;252:1299–306.

    Article  CAS  Google Scholar 

  31. Parksepp M. Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients. Nordic J Psychiatry. 2016;70:498–502. https://doi.org/10.3109/08039488.2016.1164245.

    Article  Google Scholar 

  32. Rüya-Daniela K. Social support in the general population: standardization of the Oslo social support. BMC Psychol. 2018;6:2–8. https://doi.org/10.1186/s40359-018-0249-9.

    Article  Google Scholar 

  33. WHO Assist Working Group. The alcohol, smoking and substance involvement screening test (ASSIST). J Subst. 2002;9(2):1183–94.

    Google Scholar 

  34. Sven J. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry. 2004;161:160–3.

    Article  Google Scholar 

  35. Yufita R. Prevalence of extrapyramidal side effects in patients on antipsychotics. J Psychiatry. 2017;20:5. https://doi.org/10.4172/2378-5756.1000419.

    Article  Google Scholar 

  36. Stanley N. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–8. https://doi.org/10.1016/j.ncl.2010.10.002.

    Article  Google Scholar 

  37. Gao K. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia. J Clin Psychopharmacol. 2008;28(2):203–9. https://doi.org/10.1097/JCP.0b013e318166c4d5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Deik A, Saunders-Pullman R, Luciano MS. Substance of abuse and movement disorders: complex interactions and comorbidities. Cure Drug Abuse Rev. 2012;5(3):243–53. https://doi.org/10.2174/1874473711205030243.

    Article  CAS  Google Scholar 

  39. Greenbaum L, Lerer B. Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson’s disease modifier genes. Front Neurol. 2015;6:27. https://doi.org/10.3389/fneur.2015.00027.

    Article  PubMed  PubMed Central  Google Scholar 

  40. MacNeil RR, Müller DJ. Genetics of common antipsychotic-induced adverse effects. Mol Neuropsychiatry. 2016;2(2):61–78. https://doi.org/10.1159/000445802.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Carvajal C. Poor response to treatment: beyond medication. Dialogues Clin Neurosci. 2004;6(1):93–103.

    Article  Google Scholar 

Download references

Acknowledgements

All authors would like to thank all participants of the study.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Institute Health, Dilla Referral Hospital, Dilla University, SNNP, 419, Dilla, Ethiopia

    Chalachew Kassaw

  2. Department of Technical Education, IET, Lucknow, 226021, India

    Digvijay Pandey

Authors
  1. Chalachew Kassaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Digvijay Pandey
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors were equally participate in the study.

Corresponding author

Correspondence to Chalachew Kassaw.

Ethics declarations

Conflict of Interest

There is no conflict of interest.

Ethics Approval and Consent to Participate

Written consent was obtained from the participants. Privacy and confidentiality was ensured.

Consent for Publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kassaw, C., Pandey, D. Antipsychotics Induced Movement and Sleep Disorder on Patients with Schizophrenia Attending Follow-Up Service. Sleep Vigilance 6, 115–122 (2022). https://doi.org/10.1007/s41782-021-00150-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s41782-021-00150-8

Keywords

Search

Navigation